Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 5, 2009, Pages 569-576

  Cheng, Yu Si ^a   Dai, De Zai ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CPU0213; CYP3A; Endothelin receptor antagonists; FKBP12.6

Indexed keywords

CALSTABIN 2; CPU 0213; CREATINE KINASE; CYTOCHROME P450 3A; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; FK 506 BINDING PROTEIN; ISOPRENALINE; LACTATE DEHYDROGENASE; LEPTIN; UNCLASSIFIED DRUG; CPU0213; ENDOTHELIN RECEPTOR; PYRAZOLE DERIVATIVE; TACROLIMUS BINDING PROTEIN 1B;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; WESTERN BLOTTING; ANIMAL; BLOOD; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DOWN REGULATION; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; CARDIOMEGALY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DOWN-REGULATION; ERYTHROMYCIN; HEART FAILURE; HEMODYNAMICS; ISOPROTERENOL; LEPTIN; MALE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TACROLIMUS BINDING PROTEINS; UP-REGULATION;

EID: 85047681223     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.05.0004     Document Type: Article

References (36)

1. Panda VS, Naik SR. Cardioprotective activity of Ginkgo biloba phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation. Exp Toxicol Pathol 2008; 60: 397-404.
2. Li N et al. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-218.
3. Lehnart SE et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A 2006; 103: 7906-7910.
4. Wehrens XH et al. Ryanodine receptor-targeted anti-arrhythmic therapy. Ann N Y Acad Sci 2005; 1047: 366-375.
5. Na T et al. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 39-49.
6. Zhang Y et al. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int J Cardiol 2008; 130: 463-471.
7. Tousoulis D et al. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 2008; 201: 236-247.
8. Zhang GX et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005; 65: 230-238.
9. Xu J et al. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenolinduced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol 2008; 52: 42-48.
10. Xia QG et al. Improvement of chronic heart failure by dexamethasone is not associated with downregulation of leptin in rats. Acta Pharmacol Sin 2007; 28: 202-210.
11. Dai DZ et al. Endothelin receptor antagonist activity and selective blocking the ETA and ETB of compound 0213. J China Pharm Univ 2004; 35: 552-557.
12. Guan L et al. Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice. Acta Pharmacol Sin 2006; 27: 367-371.
13. Yang TT, Dai DZ. Metabolic kinetics of CPU0213, an inhibitor of endothelin receptors, in rat liver microsomes. Asian J Pharmaceut Sci 2006; 1: 99-112.
14. Luo L et al. Effect of the endothelin receptor antagonist CPU0213, and its modulation by rifampin, on cardiac and vascular tissue following chronic isoproterenol treatment. Clin Exp Pharmacol Physiol 2008; 35: 757-765.
15. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.CurrDrugMetab 2008; 9: 310-322.
16. Higuchi S et al. Gut hyperpermiability after ischemia and reperfusion: attenuation with adrenomedullin and its binding protein treatment. Int J Clin Exp Pathol 2008; 1: 409-418.
17. Sun Y et al. Upregulation of GRP78 and caspase-12 in diastolic failing heart. Acta Biochim Pol 2008; 55: 511-516.
18. Murray DR et al. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101: 2338-2341.
19. Hu A et al. Tonic beta-adrenergic drive provokes proinflammatory and proapoptotic changes in aging mouse heart. Rejuvenation Res 2008; 11: 215-226.
20. Friese RS et al. Could beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma 2008; 64: 1061-1068.
21. GalloMP et al. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 2007; 292: H2906-H2912.
22. Bravo PE et al. Leptin and hypertension in obesity. Vasc Health Risk Manag 2006; 2: 163-169.
23. Thakker GD et al. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291: H2504-H2514.
24. Wallace AM et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104: 3052-3056.
25. Erkasap N et al. Leptin protects the cardiac myocyte cultures from hypoxic damage. Life Sci 2006; 78: 1098-1102.
26. Xu FP et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-1275.
27. Nickola MW et al. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 2000; 36: 501-505.
28. Dong F et al. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006; 47: 222-229.
29. Halcox JP et al. Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 2007; 49: 1134-1141.
30. Allan A et al. Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br J Pharmacol 2005; 146: 846-853.
31. Iyer V, Armoundas AA. Unraveling the mechanisms of catecholaminergic polymorphic ventricular tachycardia. Conf Proc IEEE Eng Med Biol Soc 2006: Suppl: 6761-6764.
32. Jiang D et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 2005; 97: 1173-1181.
33. Marks AR. Novel therapy for heart failure and exercise-induced ventricular tachycardia based on 'fixing' the leak in ryanodine receptors. Novartis Found Symp 2006; 274: 132-147.
34. Feng Y et al. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta Pharmacol Sin 2007; 28: 1746-1754.
35. Brambrink AM et al. The antibiotic erythromycin induces tolerance against transient global cerebral ischemia in rats (pharmacologic preconditioning). Anesthesiology 2006; 104: 1208-1215.
36. Dai DZ. Plasma concentrations in relation to clinical drug effects, Chapter 10. In: Dai DZ ed. A Text Book of Clinical Pharmacology. Beijing: Chinese Pharmaceutical Technology Publishing House, 2002: 109-119.